European Companies Search Engine
EU funding (€7,994,911): Accelerating the Validation of Predictive Liquid Biomarkers for Frontotemporal Dementia Diagnosis and Subclassification Hor21 Nov 2024 EU Research and Innovation programme "Horizon"
Overview
Text
Accelerating the Validation of Predictive Liquid Biomarkers for Frontotemporal Dementia Diagnosis and Subclassification
Frontotemporal dementia (FTD) has a debilitating effect on patients and their caregivers and leads to substantial economic costs. 15-30% of patients have familial FTD caused by known pathogenetic mutations. For the other 70-85% of patients, termed sporadic FTD, diagnosis is slow (~3.6 years) with frequent misdiagnosis due to clinical, genetic and molecular heterogeneity. Thus, there is great need for biomarkers for early diagnosis of sporadic FTD and its pathological subtypes. In PREDICTFTD, we will validate a set of biomarkers and create a diagnostic tool for early diagnosis of familial and sporadic FTD, which will facilitate tailored support and symptomatic treatments and care. We will apply several new approaches to achieve this: 1) we combine 11 geographically diverse cohorts of sporadic and familial FTD with retrospective and prospective longitudinal liquid biopsy samples and extensive clinical and behavioural data; 2) we are the first to use multimodal clinical and liquid biomarker data to train an AI-algorithm as a diagnostic tool for quick and early clinical FTD diagnosis; and 3) we implement a novel robust two-stage strategy for biomarker and AI algorithm validation, where phase I validates biomarkers and algorithms on a cohort of genetic and autopsied cases and phase II assesses biomarker value for diagnosis of sporadic FTD and at-risk pre-symptomatic mutation carriers. We will apply this two-stage validation strategy to address three critical clinical challenges: i) To distinguish sporadic FTD from (non-) neurodegenerative disorders that show significant clinical/symptomatic overlap, ii) To robustly detect FTD pathological subtypes in sporadic FTD and iii) pre-symptomatic identification of FTD onset. Thus, PREDICTFTD will transform FTD diagnosis, offering potential for early disease confirmation, guiding treatment decisions, facilitating patient recruitment for clinical trials, guidance of patients and caregivers, and enabling preventive measures.
Funded Companies:
| Company name | Funding amount |
| CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT | ? |
| Acondicionamiento Tarrasense Associacion | €346,400 |
| Alzheimer Europe | €300,322 |
| DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN e. V. | €853,678 |
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | €1,353,250 |
| Fondazione Ebris | €525,000 |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | €462,075 |
| Hospital Clinic de Barcelona | €0.00 |
| ITA-SUOMEN YLIOPISTO | €625,276 |
| MARTIN-LUTHER-UNIVERSITAT HALLE-WITTENBERG | €695,655 |
| STICHTING AMSTERDAM UMC | €952,571 |
| The Office of Health Economics | €329,390 |
| UAB Teraglobus | €402,045 |
| Universita Degli Studi Di Brescia | €613,625 |
| Universita Degli Studi Di Verona | €535,625 |
Source: https://cordis.europa.eu/project/id/101156175
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Développement, Neuchâtel, Switzerland.
The visualizations for "CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT - EU funding (€7,994,911): Accelerating the Validation of Predictive Liquid Biomarkers for Frontotemporal Dementia Diagnosis and Subclassification"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
